[1] 刘娟,王东江,王京华.骨髓增生异常综合征患者骨髓涂片的免疫表型分析[J].国际免疫学杂志,2010,33(5):415-416,封3.DOI:10.3760/cma.j.issn.1673-4394.2010.05.021.
[2] Wang C, Yang Y, Gao S, et al. Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies[J]. Crit Rev Oncol Hematol, 2018,122:123-132. DOI: 10.1016/j.critrevonc.2017. 12.013.
[3] 庞艳彬,田方园,史雅楠,等.骨髓增生异常综合征中的T细胞免疫[J].国际免疫学杂志,2017,40(5):584-588.DOI:10.3760/cma.j.issn.1673-4394.2017.05.025.
[4] Matos A, Magalhães SMM, Rauh MJ. Immune dysregulation and recurring mutations in myelodysplastic syndromes pathogenesis[J]. Adv Exp Med Biol, 2021,1326:1-10. DOI: 10.1007/5584_2020_608.
[5] Hochman MJ, DeZern AE. Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?[J]. Lancet Haematol, 2022,9(7):e523-e534. DOI: 10.1016/S2352-3026(22)00138-7.
[6] Barcellini W, Fattizzo B. Immune phenomena in myeloid neoplasms: an "Egg or Chicken" question[J]. Front Immunol, 2021,12:751630. DOI: 10.3389/fimmu. 2021.751630.
[7] Bienvenu AL, Traore K, Plekhanova I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients[J]. Int J Infect Dis, 2016,46:11-17. DOI: 10.1016/j.ijid.2016.03.018.
[8] Nasr M, Mohammad A, Hor M, et al. Exploring the differences in pneumocystis pneumonia infection between HIV and non-HIV patients[J]. Cureus, 2022,14(8):e27727. DOI: 10.7759/cureus.27727.
[9] Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii pneumonia[J]. Infect Dis Clin North Am, 2010,24(1):107-138. DOI: 10.1016/j.idc.2009.10.010.
[10] Ghembaza A, Vautier M, Cacoub P, et al. Risk factors and prevention of pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases[J]. Chest, 2020,158(6):2323-2332. DOI: 10.1016/j.chest.2020.05.558.
[11] Malpica L, van Duin D, Moll S. Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders[J]. Am J Hematol, 2019,94(12):1396-1412. DOI: 10.1002/ajh.25642.
[12] Zeng G, Zhang G, Chen X. Th1 cytokines, true functional signatures for protective immunity against TB?[J]. Cell Mol Immunol, 2018,15(3):206-215. DOI: 10.1038/cmi.2017.113.
[13] 刘玉坤,郭智.慢性髓系白血病与结核病共病研究进展[J].结核与肺部疾病杂志,2022,3(4):325-327.DOI:10.19983/j.issn.2096-8493.20220108.
[14] 孙勤,张青.免疫功能低下患者并发肺结核影像特征分析——附240例报告[J].海南医学,2010,21(7):29-31.DOI:10.3969/j.issn.1003-6350.2010.07.012.
[15] 伍建林,施裕新,刘晋新,等.免疫抑制宿主肺结核影像学表现及发病机制[J].中国医学计算机成像杂志,2010,16(5):415-419.DOI:10.3969/j.issn.1006-5741.2010.05.012.
[16] 王钰琪,任靖宜,康小文.二代测序技术在结核病病原学诊断、耐药性检测及流行病学监测中的应用研究进展[J].山东医药,2022,62(5):110-113.DOI:10.3969/j.issn.1002- 266X.2022.05.028.
|